{"nctId":"NCT02291679","briefTitle":"Trial of Linaclotide in Patients With Chronic Idiopathic Constipation","startDateStruct":{"date":"2014-10"},"conditions":["Chronic Idiopathic Constipation"],"count":1223,"armGroups":[{"label":"72 μg linaclotide","type":"EXPERIMENTAL","interventionNames":["Drug: Linaclotide"]},{"label":"145 μg linaclotide","type":"EXPERIMENTAL","interventionNames":["Drug: Linaclotide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Matching Placebo"]}],"interventions":[{"name":"Linaclotide","otherNames":["Linzess","Constella"]},{"name":"Matching Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient has completed a colonoscopy if one is needed according to the American Gastroenterological Association (AGA) criteria, with no clinically significant findings\n* Patient has no clinically significant findings on a physical examination and clinical laboratory tests\n* Patient meets protocol criteria for CIC: reports \\< 3 bowel movements (BMs) per week and reports one or more of the following during ≥ 25% of BMs: straining, lumpy or hard stools, sensation of incomplete evacuation during the 3 months before the diagnosis with the onset at least 6 months before the diagnosis\n* Patient is compliant with daily interactive voice response system (IVRS) calls\n* Patient reports an average of \\< 3 complete spontaneous BMs (CSBMs) and ≤ 6 SBMs per week by the IVRS over the 14 calendar days before the Randomization Visit and the calendar day of Randomization.\n\nExclusion Criteria:\n\n* Patient has history of loose or watery stools\n* Patient has symptoms of or been diagnosed with irritable bowel syndrome (IBS)\n* Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility\n* Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments\n* Patient has Bristol Stool Form Scale score of 7 during Pretreatment period.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of 12-Week CSBM Overall Responders","description":"A 12-week CSBM Overall Responder is a participant who was a CSBM Weekly Responder for at least 9 of the 12 weeks of the Treatment Period. A CSBM Weekly Responder is a participant who had a CSBM weekly frequency rate that was 3 or greater and increased by 1 or more from baseline, and completed ≥ 4 IVRS calls for the specified week.\n\nA CSBM is defined as an SBM that is associated with a sense of complete evacuation. An SBM is defined as a bowel movement BM that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":null},{"groupId":"OG001","value":"13.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null},{"groupId":"OG001","value":"86.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 12-Week CSBM Frequency Rate","description":"A participant's 12-week CSBM Frequency Rate is the CSBM rate (CSBMs/week) calculated over the 12 weeks of the Treatment Period. A CSBM is defined as an SBM that is associated with a sense of complete evacuation. An SBM is defined as a BM that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.884","spread":"0.142"},{"groupId":"OG001","value":"1.725","spread":"0.139"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 12-Week SBM Frequency Rate","description":"A participant's 12-week SBM Frequency Rate is the SBM rate (SBMs/week) calculated over the 12-weeks of the Treatment Period. An SBM is defined as a BM that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.329","spread":"0.169"},{"groupId":"OG001","value":"2.366","spread":"0.166"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 12-Week Stool Consistency Score","description":"Stool consistency was measured daily using the 7-point ordinal Bristol Stool Form Scale (BSFS; 1 = separate hard lumps like nuts \\[difficult to pass\\]; 2 = sausage shaped but lumpy; 3 = like a sausage but with cracks on surface; 4 = like a sausage or snake, smooth and soft; 5 = soft blobs with clear-cut edges \\[passed easily\\]; 6 = fluffy pieces with ragged edges, a mushy stool; 7 = watery, no solid pieces \\[entirely liquid\\]). The participant's BSFS score for the Treatment Period is the average of the non-missing BSFS scores from the SBMs reported by the participant during the 12-week Treatment Period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.065","spread":"0.076"},{"groupId":"OG001","value":"1.693","spread":"0.074"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 12-Week Straining Score","description":"Straining was measured daily using a 5-point ordinal scale (1 = not at all; 2 = a little bit; 3 = a moderate amount; 4 = a great deal; 5 = an extreme amount). The participant's straining score for the Treatment Period is the average of the non-missing straining scores from the SBMs reported by the participant during the 12-week Treatment Period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.789","spread":"0.051"},{"groupId":"OG001","value":"-1.118","spread":"0.050"}]}]}]},{"type":"SECONDARY","title":"Percentage of 12-Week CSBM Overall Responders (>1 SBM/Week Subpopulation)","description":"A 12-week CSBM Overall Responder is a participant who was a CSBM Weekly Responder for at least 9 of the 12 weeks of the Treatment Period. A CSBM Weekly Responder is a participant who had a CSBM weekly frequency rate that was 3 or greater and increased by 1 or more from baseline, and completed ≥4 IVRS calls for the specified week.\n\nA CSBM is defined as an SBM that is associated with a sense of complete evacuation. An SBM is defined as a BM that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":null},{"groupId":"OG001","value":"17.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.9","spread":null},{"groupId":"OG001","value":"82.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Month 1 CSBM Responders","description":"A Month 1 CSBM Responder is a participant who is a CSBM weekly responder for at least 3 of the 4 weeks of Month 1 of the Treatment Period. A CSBM weekly responder is a participant who had a CSBM weekly frequency rate that was 3 or greater and increased by 1 or more from baseline based on a minimum of 4 complete IVRS calls for that week.\n\nA CSBM is defined as an SBM that is associated with a sense of complete evacuation. An SBM is defined as a BM that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":null},{"groupId":"OG001","value":"14.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.8","spread":null},{"groupId":"OG001","value":"85.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Month 2 CSBM Responders","description":"A Month 2 CSBM Responder is a participant who is a CSBM weekly responder for at least 3 of the 4 weeks of Month 2 of the Treatment Period. A CSBM weekly responder is a participant who had a CSBM weekly frequency rate that was 3 or greater and increased by 1 or more from baseline based on a minimum of 4 complete IVRS calls for that week.\n\nA CSBM is defined as an SBM that is associated with a sense of complete evacuation. An SBM is defined as a BM that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":null},{"groupId":"OG001","value":"18.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.5","spread":null},{"groupId":"OG001","value":"81.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Month 3 CSBM Responders","description":"A Month 3 CSBM Responder is a participant who is a CSBM weekly responder for at least 3 of the 4 weeks of Month 3 of the Treatment Period. A CSBM weekly responder is a participant who had a CSBM weekly frequency rate that was 3 or greater and increased by 1 or more from baseline based on a minimum of 4 complete IVRS calls for that week.\n\nA CSBM is defined as an SBM that is associated with a sense of complete evacuation. An SBM is defined as a BM that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.2","spread":null},{"groupId":"OG001","value":"20.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.8","spread":null},{"groupId":"OG001","value":"79.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 12-Week Abdominal Bloating","description":"Abdominal bloating was measured daily using an 11-point NRS (0 = none; 10 = very severe). The participant's abdominal bloating score for the Treatment Period is the average of the non-missing daily participant assessments of abdominal bloating scores reported during the 12-week Treatment Period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.052","spread":"0.097"},{"groupId":"OG001","value":"-1.372","spread":"0.095"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 12-Week Abdominal Discomfort","description":"Abdominal discomfort was measured daily using an 11-point NRS (0 = none; 10 = very severe). The participant's abdominal discomfort score for the Treatment Period is the average of the non-missing daily participant assessments of abdominal discomfort scores reported during the 12-week Treatment Period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.146","spread":"0.090"},{"groupId":"OG001","value":"-1.323","spread":"0.089"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of 12-Week CSBM Overall Sustained Responders","description":"A 12-week CSBM Overall Sustained Responder is a participant who was a CSBM Weekly Responder for at least 9 of the 12 weeks of the Treatment Period, including ≥ 3 of the last 4 weeks. A CSBM Weekly Responder is a participant who had a CSBM weekly frequency rate that was 3 or greater and increased by 1 or more from baseline, and completed ≥ 4 IVRS calls for the specified week.\n\nA CSBM is defined as an SBM that is associated with a sense of complete evacuation. An SBM is defined as a BM that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":null},{"groupId":"OG001","value":"12.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null},{"groupId":"OG001","value":"87.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":401},"commonTop":["Diarrhea"]}}}